Decentralized care pathway for cancer patients receiving oral treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This proof-of-concept study aims to assess the feasibility of a decentralized care pathway for patients with solid cancers or haematological malignancies who are receiving oral chemotherapy. The study will involve 33 patients and will replace traditional hospital visits with home visits by an advanced practice nurse to enhance patient care and convenience. The goal is to evaluate whether this approach can improve treatment adherence and patient satisfaction while maintaining safety and efficacy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patient over 18.
2. A patient with solid cancer or haematological malignancy receiving oral retroceded therapy as part of standard management.
3. Patient with a performance index (ECOG): 0-2.
4. Patient contactable by telephone for follow-up by the Advanced Practice Nurse.
5. Patient willing to make two home visits within 6 months of inclusion.

Exclusion Criteria:

1. Pregnant or breast-feeding patient.
2. Any psychological, family, geographical or social condition which, in the judgement of the oncologist, could potentially prevent the collection of informed consent or hinder compliance with the study protocol.
3. Patients deprived of their liberty by administrative or legal decision, or patients under guardianship.

Where it's running

• Institut Universitaire du Cancer de Toulouse - Oncopole
  Toulouse, France Recruiting

Study contacts

• Study coordinator: Pierre BORIES
• Email: Bories.pierre@iuct-oncopole.fr
• Phone: 05 31 15 65 14

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AK138D1 for advanced solid tumors

  We will try AK138D1 given by IV in adults with advanced solid tumors that haven't responded to standard treatments to find a safe dose and see if it can shrink tumors.

  Recruiting Phase 1 Akeso · Harbin, Heilongjiang · NCT07281326

• PRaG-1 Plus PRaG Therapy with Radiation and Immunotherapy in Older Adults with Advanced Solid Tumors

  This study tests whether giving PRaG-1 Cordycepin tablets together with radiation, immune-boosting injections, and PD-1/PD-L1 inhibitors can help people aged 65 and older with advanced solid tumors.

  Recruiting Phase 2 Second Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07267234

• Cordycepin (PRaG-1) to raise CD8+ T‑cell counts after treatment for solid tumors

  This trial will test whether PRaG-1 (cordycepin) can raise low CD8+ T‑cell counts in adults who are tumor‑free after treatment for solid cancers.

  Recruiting Phase 2 Second Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07258160

• TC-G203 treatment for GPC3-positive advanced solid tumors

  This trial will test a single-dose TC-G203 cell therapy to see if it is safe and helps adults with GPC3-positive recurrent or metastatic solid tumors who have already tried other treatments.

  Recruiting Early Phase 1 Beijing GoBroad Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07242417

• Urolithin A (MitoPure®) with immune checkpoint inhibitors for newly diagnosed solid tumors

  This trial tests whether taking urolithin A (MitoPure®) alongside first-line immune checkpoint inhibitor therapy changes immune responses in adults with newly diagnosed solid tumors.

  Recruiting Goethe University · Frankfurt · NCT07161310

• How the CES1 liver enzyme affects capecitabine levels in people with colorectal, gastric, or esophageal cancer

  This project will see if differences in the CES1 enzyme change how capecitabine is processed and whether that affects side effects like hand‑foot syndrome in adults starting capecitabine with oxaliplatin for colorectal, gastric, or esophageal cancer.

  Recruiting Erasmus Medical Center · Rotterdam · NCT07114627

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.